Japan Tobacco, Leo Pharma deal

Japan Tobacco granted Leo exclusive, ex-Japan rights to develop and commercialize JTE-052 for topical use to treat dermatological indications. The oral JAK kinase (JAK) inhibitor is in Phase I trial...